The Novo-backed musculoskeletal disease therapy developer's market capitalisation stood at $1.6bn as of close of trading yesterday.
Edgewise Therapeutics, a US-based musculoskeletal disease drug developer that counts pharmaceutical firm Novo as an investor, closed an initial public offering on the Nasdaq Global Market at $202m on Tuesday. The company raised an initial $176m last week, pricing 11 million shares at $16.00 each. Its shares closed trading at $32.50 yesterday, equating to a…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
